(WVE) Wave Life Sciences - Ratings and Ratios

Exchange: NASDAQ • Country: Singapore • Currency: USD • Type: Common Stock • ISIN: SG9999014716

WVE: RNA, Medicines, Oligonucleotides, Therapeutics

Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology company that specializes in the design, development, and commercialization of innovative RNA medicines. At the core of their approach is PRISM, a proprietary discovery and drug development platform that integrates multiple RNA modalities, cutting-edge chemistry, and deep insights into human genetics. This platform is designed to address a wide range of rare and prevalent disorders by delivering precise and targeted therapeutic solutions.

The companys pipeline is diverse, focusing on several high-impact therapeutic areas. WVE-006 is an RNA editing oligonucleotide currently in development for the treatment of alpha-1 antitrypsin deficiency, a genetic disorder that can lead to severe lung and liver disease. Additionally, Wave is advancing an siRNA clinical candidate for obesity and other metabolic disorders, targeting a condition that affects millions globally. WVE-N531, an exon-skipping oligonucleotide, is being developed for Duchenne muscular dystrophy, a devastating genetic disorder affecting muscle function. Furthermore, WVE-003, an antisense silencing oligonucleotide, is in development for Huntingtons disease, a progressive neurodegenerative disorder with significant unmet medical need.

Wave has established strategic collaborations to enhance its research and development capabilities. Notably, the company has partnered with GlaxoSmithKline (GSK) to co-develop and commercialize oligonucleotide therapeutics, leveraging GSKs extensive expertise in drug development and commercialization. Another key partnership is with Takeda Pharmaceutical Company Limited, focusing on CNS disorders, an area where RNA-based therapies hold great promise. Additionally, Wave has collaborated with Asuragen, Inc. to develop companion diagnostics for its allele-selective therapeutic programs targeting Huntingtons disease, ensuring that patients can benefit from personalized treatment approaches.

Founded in 2012 and headquartered in Singapore, Wave Life Sciences has rapidly emerged as a leader in the RNA therapeutics space. The companys market capitalization stands at approximately $1.7 billion, reflecting investor confidence in its innovative platform and pipeline. While the company is currently pre-revenue, its focus on advancing a versatile RNA platform positions it as a high-risk, high-reward opportunity in the biotechnology sector. Investors should closely monitor the progress of its clinical programs and collaborations, as success in any of these areas could significantly impact the companys valuation.

For more information, visit their website at https://www.wavelifesciences.com.

Additional Sources for WVE Stock

WVE Stock Overview

Market Cap in USD 1,443m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2015-11-11

WVE Stock Ratings

Growth 5y 18.4%
Fundamental -35.6%
Dividend 0.0%
Rel. Strength Industry 57.8
Analysts 4.6/5
Fair Price Momentum 9.24 USD
Fair Price DCF -

WVE Dividends

No Dividends Paid

WVE Growth Ratios

Growth Correlation 3m -90.2%
Growth Correlation 12m 70.8%
Growth Correlation 5y -12.5%
CAGR 5y 4.88%
CAGR/Max DD 5y 0.05
Sharpe Ratio 12m -0.15
Alpha 38.83
Beta 2.49
Volatility 91.48%
Current Volume 743.4k
Average Volume 20d 1082.2k
What is the price of WVE stocks?
As of March 15, 2025, the stock is trading at USD 10.22 with a total of 743,384 shares traded.
Over the past week, the price has changed by +8.72%, over one month by -5.46%, over three months by -24.01% and over the past year by +59.19%.
Is Wave Life Sciences a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Wave Life Sciences (NASDAQ:WVE) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -35.63 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of WVE as of March 2025 is 9.24. This means that WVE is currently overvalued and has a potential downside of -9.59%.
Is WVE a buy, sell or hold?
Wave Life Sciences has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy WVE.
  • Strong Buy: 7
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for WVE stock price target?
According to ValueRays Forecast Model, WVE Wave Life Sciences will be worth about 10.9 in March 2026. The stock is currently trading at 10.22. This means that the stock has a potential upside of +6.65%.
Issuer Forecast Upside
Wallstreet Target Price 22.9 124.2%
Analysts Target Price 22.3 118.2%
ValueRay Target Price 10.9 6.7%